Your browser doesn't support javascript.
loading
B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS.
Wang, Sophia S; Vajdic, Claire M; Linet, Martha S; Slager, Susan L; Voutsinas, Jenna; Nieters, Alexandra; Casabonne, Delphine; Cerhan, James R; Cozen, Wendy; Alarcón, Graciela; Martínez-Maza, Otoniel; Brown, Elizabeth E; Bracci, Paige M; Turner, Jennifer; Hjalgrim, Henrik; Bhatti, Parveen; Zhang, Yawei; Birmann, Brenda M; Flowers, Christopher R; Paltiel, Ora; Holly, Elizabeth A; Kane, Eleanor; Weisenburger, Dennis D; Maynadié, Marc; Cocco, Pierluigi; Foretova, Lenka; Breen, Elizabeth Crabb; Lan, Qing; Brooks-Wilson, Angela; De Roos, Anneclaire J; Smith, Martyn T; Roman, Eve; Boffetta, Paolo; Kricker, Anne; Zheng, Tongzhang; Skibola, Christine F; Clavel, Jacqueline; Monnereau, Alain; Chanock, Stephen J; Rothman, Nathaniel; Benavente, Yolanda; Hartge, Patricia; Smedby, Karin E.
Afiliação
  • Wang SS; Division of Health Analytics, Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Monrovia, California.
  • Vajdic CM; Centre for Big Data Research in Health, The University of New South Wales, Sydney, New South Wales, Australia.
  • Linet MS; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Slager SL; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Voutsinas J; Division of Health Analytics, Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Monrovia, California.
  • Nieters A; The Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany.
  • Casabonne D; Unit of Infections and Cancer, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program - Epibell, IDIBELL, Institut Català d' Oncologia/IDIBELL, Barcelona, Spain.
  • Cerhan JR; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Cozen W; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Alarcón G; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California.
  • Martínez-Maza O; Division of Clinical Immunology and Rheumatology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama.
  • Brown EE; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Bracci PM; Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Turner J; Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California.
  • Hjalgrim H; Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama.
  • Bhatti P; O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama.
  • Zhang Y; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
  • Birmann BM; Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, New South Wales, Australia.
  • Flowers CR; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Paltiel O; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Holly EA; British Columbia Cancer Research Center, Vancouver, British Columbia, Canada.
  • Kane E; Department of Cancer Prevention and Control at the National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Weisenburger DD; Channing Division of Network Medicine, Department of Medicine Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Maynadié M; Winship Cancer Institute, Emory University, Atlanta, Georgia.
  • Cocco P; Department of Hematology, The Hebrew University-Hadassah Braun School of Public Health and Community Medicine, Hadassah University Medical Center, Jerusalem, Israel.
  • Foretova L; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
  • Breen EC; Department of Health Sciences, University of York, York, United Kingdom.
  • Lan Q; Department of Pathology, City of Hope, Duarte, California.
  • Brooks-Wilson A; Registry of Hematological Malignancies of Cote d'Or, INSERM U1231, Burgundy University and University Hospital, Dijon, France (Maynadie).
  • De Roos AJ; Occupational Health Section, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Smith MT; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Roman E; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Boffetta P; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Kricker A; Department of Biomedical Physiology and Kinesiology, Faculty of Science, Simon Fraser University, Vancouver, British Columbia, Canada.
  • Zheng T; Department of Environmental and Occupational Health, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania.
  • Skibola CF; Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California.
  • Clavel J; Department of Health Sciences, University of York, York, United Kingdom.
  • Monnereau A; Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York.
  • Chanock SJ; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Rothman N; Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Benavente Y; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.
  • Hartge P; Winship Cancer Institute, Emory University, Atlanta, Georgia.
  • Smedby KE; Centre of Research in Epidemiology and Statistics (CRESS), UMR1153, INSERM, Université de Paris, Paris, France.
Cancer Epidemiol Biomarkers Prev ; 31(5): 1103-1110, 2022 05 04.
Article em En | MEDLINE | ID: mdl-35244686
ABSTRACT

BACKGROUND:

A previous International Lymphoma Epidemiology (InterLymph) Consortium evaluation of joint associations between five immune gene variants and autoimmune conditions reported interactions between B-cell response-mediated autoimmune conditions and the rs1800629 genotype on risk of B-cell non-Hodgkin lymphoma (NHL) subtypes. Here, we extend that evaluation using NHL subtype-specific polygenic risk scores (PRS) constructed from loci identified in genome-wide association studies of three common B-cell NHL subtypes.

METHODS:

In a pooled analysis of NHL cases and controls of Caucasian descent from 14 participating InterLymph studies, we evaluated joint associations between B-cell-mediated autoimmune conditions and tertile (T) of PRS for risk of diffuse large B-cell lymphoma (DLBCL; n = 1,914), follicular lymphoma (n = 1,733), and marginal zone lymphoma (MZL; n = 407), using unconditional logistic regression.

RESULTS:

We demonstrated a positive association of DLBCL PRS with DLBCL risk [T2 vs. T1 OR = 1.24; 95% confidence interval (CI), 1.08-1.43; T3 vs. T1 OR = 1.81; 95% CI, 1.59-2.07; P-trend (Ptrend) < 0.0001]. DLBCL risk also increased with increasing PRS tertile among those with an autoimmune condition, being highest for those with a B-cell-mediated autoimmune condition and a T3 PRS [OR = 6.46 vs. no autoimmune condition and a T1 PRS, Ptrend < 0.0001, P-interaction (Pinteraction) = 0.49]. Follicular lymphoma and MZL risk demonstrated no evidence of joint associations or significant Pinteraction.

CONCLUSIONS:

Our results suggest that PRS constructed from currently known subtype-specific loci may not necessarily capture biological pathways shared with autoimmune conditions. IMPACT Targeted genetic (PRS) screening among population subsets with autoimmune conditions may offer opportunities for identifying those at highest risk for (and early detection from) DLBCL.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Linfoma Folicular / Linfoma Difuso de Grandes Células B Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Linfoma Folicular / Linfoma Difuso de Grandes Células B Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article